{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:33:40Z","timestamp":1791894820547,"version":"4.3.4"},"reference-count":81,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Drug-induced autoimmune hepatitis (DIAIH) is a relatively new subtype of idiosyncratic drug-induced liver injury (iDILI), but the features of DIAIH have been variably described due to the inhomogeneity of assessed study cohorts. The aim of this analysis is to harmonize DIAIH cohorts by unifying causality assessments, which may help characterize the features of DIAIH. Methods: Published reports of DIAIH cases were evaluated for the causality assessment methods used to verify the diagnosis of DIAIH. This disorder consists of two parts, i.e., the iDILI part and the autoimmune (AIH) part, whereby each part needs a specific diagnostic algorithm. The validated and scoring Roussel Uclaf Causality Assessment (RUCAM) is privileged for assessing the iDILI part, and the validated, simplified AIH score is the perfect choice for evaluating the AIH part. The analysis of DIAIH publications revealed that 12\/20 reports (60%) presented cases assessed by both the RUCAM and the simplified AIH score, providing 49 drugs and drug combinations as causative drugs in up to 25 cases of DIAIH. Serum alanine aminotransferase activities of up to 3489 UL and high titers of autoimmune parameters such as anti-nuclear antibodies, anti-smooth-muscle antibodies, and soluble liver antigen antibodies supported DIAIH diagnosis. In contrast, 4\/20 reports (20%) applied only RUCAM, and 2\/20 reports (10%) used only the simplified AIH score; these 6 reports therefore provided insufficient criteria for a valid DIAIH diagnosis. Moreover, 2\/20 reports (10%) did not use any causality algorithm, providing elusive features of DIAIH. While DIAIH is clearly restricted to drugs as responsible agents, this term is erroneously used to refer to disease induced by non-drugs such as herbs, green tea, dimethoate (an organophosphate insecticide), dietary supplements, biologics, herbal remedies, different viruses, and bacteria, as well as vaccines. For diseases induced by these agents, a better term could be, for instance, non-drug-induced autoimmune hepatitis. Drug cessation and immunotherapy with corticosteroids and azathioprine comprise the treatment of choice. The characteristics of DIAIH can best be described if both the RUCAM and the simplified AIH score are used concomitantly.<\/jats:p>","DOI":"10.3390\/diagnostics15131588","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:42:34Z","timestamp":1750664554000},"page":"1588","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-1200","authenticated-orcid":false,"given":"Rolf","family":"Teschke","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Germany"},{"name":"Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt\/Main, D-60629 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Eickhoff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Germany"},{"name":"Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt\/Main, D-60629 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-1505","authenticated-orcid":false,"given":"Gaby","family":"Danan","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Consultancy, Rue des Ormeaux, 75020 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_3","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2025, February 20). Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ke, L., Lu, C., Shen, R., Lu, T., Ma, B., and Hua, Y. (2020). Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010\u20132019). Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00842"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: A comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_6","first-page":"1","article-title":"Selected highlights and controversies of drug-induced liver injury from the recent literature","volume":"1","author":"Rosenberg","year":"2020","journal-title":"World J. Gastroenterol. Hepatol. Endosc. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40264-021-01109-4","article-title":"Drug-induced liver injury: Highlights and controversies in the recent literature","volume":"44","author":"Clinton","year":"2021","journal-title":"Drug Saf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jceh.2012.05.002","article-title":"An update on drug-induced liver injury","volume":"2","author":"Devarbhavi","year":"2012","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_9","first-page":"6331923","article-title":"A case of delayed hepatic injury associated with teriflunomide use as assessed for causality using the updated RUCAM","volume":"2022","author":"Wurzburger","year":"2022","journal-title":"Case Rep. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shi, X., Lao, D., Xu, Q., Li, X., and Lv, Q. (2022). A case report of drug-induced liver injury after tigecycline administration: Histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07258-w"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2024). Human Leucocyte Antigen genetics in idiosyncratic drug-induced liver injury with evidence based on the Roussel Uclaf Causality Assessment Method. Medicines, 11.","DOI":"10.3390\/medicines11040009"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bcp.15054","article-title":"Association of human leukocyte antigen-B*13:01 with dapsone-induced liver injury","volume":"88","author":"Devarbhavi","year":"2022","journal-title":"Brit J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jcpt.12760","article-title":"Fluoxetine-induced Stevens-Johnson syndrome and liver injury","volume":"44","author":"Agrawal","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/hep.28270","article-title":"Drug-induced liver injury associated with Stevens-Johnson syndrome\/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases","volume":"63","author":"Devarbhavi","year":"2016","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s10620-022-07777-1","article-title":"Clinical and liver biochemistry phenotypes, and outcome in 133 patients with anti-seizure drug-induced liver injury","volume":"68","author":"Devarbhavi","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ortega-Alonso, A., Stephens, C., Lucena, M.I., and Andrade, R.J. (2016). Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050714"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2023). Advances in idiosyncratic drug induced liver injury issues: New clinical and mechanistic analysis due to Roussel Uclaf Causality Assessment Method use. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310855"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"bcr2012006543","DOI":"10.1136\/bcr-2012-006543","article-title":"Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury","volume":"2012","author":"Nicoll","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/apt.15168","article-title":"A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane","volume":"49","author":"Bishop","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.gastha.2023.02.002","article-title":"Distinction of drug-induced liver injury from autoimmune hepatitis in patients with acute liver injury: Proposal of a combination of diagnostic scores","volume":"2","author":"Kakisaka","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.01.029","article-title":"Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry","volume":"75","author":"Stephens","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000528329","article-title":"Relapse and need for extended immunosuppression: Novel features of drug-induced autoimmune hepatitis","volume":"104","author":"Weber","year":"2023","journal-title":"Digestion"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3350\/cmh.2020.0189","article-title":"Recent updates on the management of autoimmune hepatitis","volume":"27","author":"Komori","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e9050","DOI":"10.1002\/ccr3.9050","article-title":"Acute onset nitrofurantoin-induced autoimmune hepatitis after urinary tract infection treatment","volume":"12","author":"Chaudhary","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sebode, M., Schulz, L., and Lohse, A.W. (2017). \u201cAutoimmune(-like)\u201d drug and herb induced liver injury: New insights into molecular pathogenesis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091954"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2016). RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Naseralallah, L.M., Aboujabal, B.A., Geryo, N.M., Al Boinin, A., Al Hattab, F., Akbar, R., Umer, W., Abdul Jabbar, L., and Danjuma, M.I. (2022). The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268705"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Olsson","year":"2005","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Teschke, R., and Danan, G. (2020). Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993\u2013mid 2020: A comprehensive analysis. Medicines, 7.","DOI":"10.3390\/medicines7100062"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chen, M., and Will, Y. (2018). Causality assessment methods in drug-induced liver injury. Drug-Induced Liver Toxicity (Chapter 27), Springer Nature. Methods in Pharmacology and Toxicology.","DOI":"10.1007\/978-1-4939-7677-5"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/hep.32440","article-title":"Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation","volume":"76","author":"Danan","year":"2022","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/hep.22825","article-title":"Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients","volume":"49","author":"Muratori","year":"2009","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1053\/j.gastro.2015.04.027","article-title":"Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment","volume":"148","author":"Teschke","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5223\/pghn.2018.21.2.118","article-title":"Accuracy of the 2008 simplified criteria for the diagnosis of autoimmune hepatitis in children","volume":"21","year":"2018","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/2050640617711632","article-title":"Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort","volume":"6","author":"Wobser","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_42","first-page":"108","article-title":"Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis","volume":"6","author":"Chandok","year":"2010","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cld.321","article-title":"Autoimmune hepatitis: Diagnostic criteria and serological testing","volume":"3","author":"Vergani","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jceh.2018.10.006","article-title":"Accuracy of the simplified criteria for autoimmune hepatitis in children: Systematic review and decision analysis","volume":"9","author":"Bovo","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5152\/tjg.2021.19305","article-title":"Evaluation of validity and efficiency of diagnostic criteria in autoimmune hepatitis in children","volume":"32","author":"Imanieh","year":"2021","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MPG.0b013e3181fc1e0b","article-title":"Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children","volume":"52","author":"Hiejima","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2011.11.030","article-title":"Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children","volume":"10","author":"Mileti","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/etm.2013.1366","article-title":"Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis","volume":"7","author":"Li","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3350\/cmh.2024.0131","article-title":"Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis","volume":"30","author":"Komori","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2010.07.013","article-title":"Recognizing autoimmune hepatitis: Scores help, but no more","volume":"54","author":"Lohse","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: Analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jgh3.12054","article-title":"Differential characteristics in drug-induced autoimmune hepatitis","volume":"2","author":"Santos","year":"2018","journal-title":"JGH Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14195","article-title":"Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis","volume":"39","author":"Weber","year":"2019","journal-title":"Liver Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/liv.15623","article-title":"Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries","volume":"43","author":"Castiella","year":"2023","journal-title":"Liver Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1111\/hepr.12532","article-title":"Natural history and outcomes in drug-induced autoimmune hepatitis","volume":"46","author":"Yeong","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: A minireview","volume":"28","author":"Tan","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_59","first-page":"e47807","article-title":"Atorvastatin-induced autoimmune hepatitis: A case report","volume":"15","author":"Tse","year":"2023","journal-title":"Cureus"},{"key":"ref_60","first-page":"e7299","article-title":"Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jgh3.12862","article-title":"Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: A case-control study","volume":"7","author":"Hassoun","year":"2023","journal-title":"JGH Open"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis","volume":"51","author":"Talwalkar","year":"2010","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"Kosinski","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bergmann","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Gudbjornsson","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/liv.14224","article-title":"Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs","volume":"39","author":"Valgeirsson","year":"2019","journal-title":"Liver Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ueg2.12499","article-title":"Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study","volume":"12","author":"Chung","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_68","first-page":"7343805","article-title":"Menotrophin induced autoimmune hepatitis","volume":"2019","author":"Alqrinawi","year":"2019","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5223\/pghn.2018.21.4.347","article-title":"Minocycline-induced autoimmune hepatitis: A rare but important cause of drug-induced autoimmune hepatitis","volume":"21","author":"Harmon","year":"2018","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"20420986241270866","DOI":"10.1177\/20420986241270866","article-title":"Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction","volume":"15","author":"Fortunati","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3390\/clinpract13060125","article-title":"A case report: Idiopathic or drug-induced autoimmune hepatitis-can we draw a line?","volume":"13","author":"Vukojevic","year":"2023","journal-title":"Clin. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4254\/wjh.v6.i4.160","article-title":"Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease","volume":"6","author":"Castiella","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kawano, M., Yano, Y., Yamamoto, A., Yasutomi, E., Inoue, Y., Kitadai, J., Yoshida, R., Matsuura, T., Shiomi, Y., and Ueda, Y. (2024). Risk factors for immune checkpoint inhibitor-induced liver injury and the significance of liver biopsy. Diagnostics, 14.","DOI":"10.3390\/diagnostics14080815"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liu, Z., Zhu, Y., Xie, H., and Zou, Z. (2023). Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1077468"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Swanson, L.A., Kassab, I., Tsung, I., Schneider, B.J., and Fontana, R.J. (2022). Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.984940"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Raghav, A., and Jeong, G.B. (2024). Phase I\u2013IV drug trials on hepatocellular carcinoma in Asian populations: A systematic review of ten years of studies. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202406.0517.v1"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/apt.18276","article-title":"Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM","volume":"60","author":"Hountondji","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Sakulsaengprapha, V., Wasuwanich, P., Naraparaju, G., Korotkaya, Y., Thawillarp, S., Oshima, K., Karwowski, C., Scheimann, A.O., and Karnsakul, W. (2023). Applicability of International Autoimmune Hepatitis Group (IAIGH) scoring system for autoimmune hepatitis in pediatrics. Biology, 12.","DOI":"10.3390\/biology12030479"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/bcp.13593","article-title":"Drug induced liver injury with analysis of alternative causes as confounding variables","volume":"84","author":"Teschke","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Teschke, R. (2025). Immunology highlights of four major idiosyncratic DILI subtypes verified by the RUCAM: A new evidence-based classification. Livers, 5.","DOI":"10.3390\/livers5010008"},{"key":"ref_81","first-page":"339","article-title":"Liver injury in immune Stevens-Johnson syndrome and toxic epidermal necrolysis: Five new classification types","volume":"13","author":"Teschke","year":"2025","journal-title":"J. Clin. Trans. Hepatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/13\/1588\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:56:58Z","timestamp":1760032618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/13\/1588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":81,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["diagnostics15131588"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15131588","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}